RxDoctor Payments Data

Gary Cohen, MD

Internal Medicine · Bloomfield, CTNPI 1346264413

Payments from drug & device makers

$2,779in general payments, 2019–2025

Across 145 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$624
  • Amgen$220
  • Astellas Pharma US Inc$202
  • AstraZeneca$197
  • Lilly USA, LLC$147
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$145
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$2,68997%
  • Education$903%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,779 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$47,856
Medicare patients
116
Services billed
837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate68$77,090
JardianceEmpagliflozin58$77,004
EliquisApixaban58$56,819
FarxigaDapagliflozin Propanediol33$36,016
TrulicityDulaglutide14$30,778
MyrbetriqMirabegron33$26,471
Bydureon BciseExenatide Microspheres11$22,109
OzempicSemaglutide14$21,360
XareltoRivaroxaban14$17,801
Levothyroxine Sodium152$3,093
SymbicortBudesonide/Formoterol Fumarate12$2,705
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,595
Potassium Chloride57$2,559
Atorvastatin Calcium315$2,304
Amlodipine-AtorvastatinAmlodipine/Atorvastatin16$2,241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$13$77,09068 claims
Boehringer IngelheimJardiance$19$77,00458 claims
PfizerEliquis$145$56,81958 claims
AstraZenecaFarxiga, Symbicort$197$38,72145 claims
Lilly USA, LLCTrulicity$147$30,77814 claims
Astellas Pharma US IncMyrbetriq$202$26,47133 claims
Novo NordiskOzempic$624$21,36014 claims
Johnson & JohnsonXarelto$50$17,80114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Bloomfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →